|
Wednesday 19th January 2022 |
Text too small? |
At a Special Meeting held online today, Wednesday 19 January 2022, Rua Bioscience shareholders voted in favour of Rua acquiring Zalm Therapeutics. Shareholders were asked to vote on a resolution being:
That the issue of:
• 8,140,000 new ordinary shares (Initial Shares); and
• 16,280,000 equity securities having the right to convert into ordinary shares on achievement of the milestones described in the explanatory notes (Performance Shares) to the shareholders of Zalm Therapeutics Limited (which may together eventually result in those subscribers holding 28,735,632 fully paid ordinary shares in the Company) be approved for all purposes, including for the purposes of NZX Listing Rule 4.2.1(a).
As required by NZX Listing Rule 6.1, all voting was conducted by a poll. The resolution was passed by the required majority, and the result of the voting is attached.
Please see the link below for details
Source: Rua Bioscience Limited
No comments yet
October 12th Morning Report
TEM - Transaction in Own Shares
October 9th Morning Report
VGL - NZX Tech Investor Day Presentation
October 8th Morning Report
IFT - CDC Independent Valuation
TEM - Transaction in Own Shares
October 7th Morning Report
Devon Funds Morning Note - 06 October 2026
AFT reports double digit revenue growth in 1H FY27